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Abstract
Frizzled 8-associated Antiproliferative Factor (APF) is a sialoglycopeptide urinary biomarker of interstitial cystitis/painful
bladder syndrome (IC/PBS), a chronic condition of unknown etiology with variable symptoms that generally include pelvic
and/or perineal pain, urinary frequency, and urgency. We previously reported that native human APF suppresses the
proliferation of normal bladder epithelial cells through a mechanism that involves increased levels of p53. The goal of this
study was to delineate the regulatory mechanism whereby p53 expression is regulated by APF. Two APF-responsive cell
lines (T24 bladder carcinoma cells and the immortalized human bladder epithelial cell line, TRT-HU1) were treated with
asialo-APF (as-APF), a chemically synthesized form of APF. Biochemical analysis revealed that as-APF increased p53 levels in
two ways: by decreasing ubiquitin specific protease 2a (USP2a) expression leading to enhanced ubiquitination of murine
double minute 2 E3 ubiquitin ligase (MDM2), and by suppressing association of p53 with MDM2, thus impairing p53
ubiquitination. Biological responses to as-APF were suppressed by increased expression of wild type, but not mutant USP2a,
which enhanced cell growth via upregulation of a cell cycle mediator, cyclin D1, at both transcription and protein levels.
Consistent with this, gene silencing of USP2a with siRNA arrested cell proliferation. Our findings suggest that APF
upregulates cellular p53 levels via functional attenuation of the USP2a-MDM2 pathway, resulting in p53 accumulation and
growth arrest. These data also imply that targeting USP2a, MDM2, p53 and/or complex formation by these molecules may
be relevant in the development of novel therapeutic approaches to IC/PBS.
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Introduction
More than one out of 77 people (3–8 million women and 1–4
million men) have been diagnosed with interstitial cystitis/painful
bladder syndrome (IC/PBS) in the U.S. [1,2], resulting in a great
public health burden [3–5]. A specific diagnostic test is not yet
available for IC/PBS, and inclusive and exclusive clinical
diagnostic criteria listed in published NIDDK or AUA guidelines
(e.g., results from urinalysis, urine culture, cystoscopy, biopsy of
the bladder wall and urethra, and bladder distention) [6–10] are
not consistently applied in general practice. Moreover, treatment
of IC/PBS also remains challenging, as the use of a commonly
prescribed IC/PBS medication, pentosan polysulfate (Elmiron),
the first FDA-approved oral drug for this disease, results in
symptom relief for only 30–60% of patients, and has side effects
such as hair loss and gastrointestinal disturbance [1,11]. Elucida-
tion of the pathogenic mechanisms of IC/PBS is essential, as this
may lead to the discovery of new approaches to therapy and to
biomarkers for improved diagnosis[12–16].
Anti-proliferative factor (APF), a short sialoglycopeptide whose
primary structure is 100% homologous to the putative sixth
transmembrane domain of frizzled 8 (a Wnt receptor), has been
proposed as a candidate biomarker for IC/PBS, based on the
finding of significantly increased APF activity levels in urine from
IC/PBS patients compared to normal controls [17,18]. APF has
been directly implicated in the pathogenesis of IC/PBS, as bladder
epithelial cells from IC/PBS patients that produce this factor
consistently proliferate at an abnormally slow rate compared to
explanted epithelial cells from matched controls, and because
purified human APF is a bladder epithelial cell growth inhibitor
[15,19]. Decreased cell proliferation along with reduced tight
junction protein expression in response to APF is consistent with
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e50392thinning, denudation and increased permeability observed in
bladder epithelium of IC/PBS patients [20,21].
APF signaling is mediated by the membrane receptor cytoskel-
eton-associated protein 4 (CKAP4), also known as CLIMP63, and
requires S-acylation of CKAP4 by the palmitoyl acyltransferase
DHHC2 [22–24]. The mechanism by which APF inhibits cell
proliferation appears to involve downregulation of heparin binding
EGF-like growth factor (HB-EGF) [25], with possibly related
inhibition of AKT signaling [26]. APF also activates p38/MAPK
signaling [27,28] and upregulates p53 and p21 at both the protein
and mRNA levels [26]. However, the specific mechanism by
which APF regulates p53 levels in bladder epithelial cells is not
clearly understood.
P53 is a tightly regulated transcription factor that arrests cell
cycle transit or promotes cell senescence or apoptosis in response
to stress stimuli. Activation of p53 results in accumulation of the
protein in the nucleus and association with its functional partners
[29–32]. Ubiquitination and degradation by the 26S proteasome
are triggered by association of p53 with the RING-finger ubiquitin
E3 ligase MDM2 [33–35]. This interaction is disrupted when cells
detect DNA damage or other stresses, leading to stabilization and
p53 activation. Overexpression of MDM2 is observed in many
cancer types and correlates with aberrant p53 inactivation
[32,36,37]; however, the role of MDM2 in bladder pathology is
still poorly understood.
In this study we report findings of an investigation into the
specific molecular mechanism whereby APF regulates p53 in
bladder epithelial cells. Our results identify an important signaling
network involving MDM2 and the de-ubiquitinase, USP2a, which
is activated in response to chemically synthesized APF.
Results
Functionally Active Synthetic Asialo-APF (as-APF) Inhibits
Proliferation by Regulation of p53
To understand the mechanism whereby p53 levels are increased
in response to APF in bladder epithelial cells, asialylated-APF (as-
APF) (2-3Galb1-3GalNAca-O-TVPAAVVVA), and its inactive
nonglycosylated negative control peptide (TVPAAVVVA) were
used in this study [38]. Consistent with the inhibition of cell
proliferation seen in responsive to native APF in T24 bladder cells
as determined by crystal violet staining, 3 days of treatment with
synthetic as-APF increased p53 protein levels in a concentration-
dependent manner (Fig. 1A). 1 mM as-APF significantly increased
Figure 1. p53 is required for the growth inhibitory effect induced by the chemically synthesized as-APF. (A) Dose and time-dependent
growth inhibitory effect of synthetic as-APF. T24 cells were incubated with varying doses of as-APF as indicated. Cell proliferation was determined by
crystal violet assay at 0, 1, and 3 days after treatment. Experiments were performed in triplicate. (B) as-APF increases p53 expression. T24 cells were
incubated as-APF (0, 0.01, 0.1 or 1 mM) containing serum free medium for 3 days. Cell lysates were prepared for immunoblot analysis using antibodies
against p53 or b-actin. Fold changes of p53/b-actin are shown in the graph. (C) Gene silencing of p53 recovers growth arrest by as-APF. T24 cells were
transiently transfected using siRNAs for p53 (sip53) or control (siCtrl). 24 h after transfection, cells were serum starved for 16 h and incubated with as-
APF containing medium (1 mM) for additional 3 days. Data are expressed as mean6SD. *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0050392.g001
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inhibitory effect of as-APF on cell proliferation. In comparison, the
control mock peptide had no effect on p53 levels (not shown). To
assess the involvement of p53 in growth suppression by as-APF,
RNA interference experiments were performed using p53 siRNA
duplexes. Knockdown of p53 diminished the inhibitory effect of
synthetic as-APF on cell growth (Fig. 1C), consistent with previous
observations using native HPLC-purified APF [39]. Combined
with previous observations on the biological effects of as-APF
[15,26,38], our results indicate that as-APF has the same activity as
the HPLC-purified native APF peptide from the spent cell
medium of bladder explants from patients who were diagnosed
with IC/PBS [15,21,23,25].
as-APF Enhances p53 Stability via Suppression of MDM2
We next sought to understand the molecular mechanism
whereby the p53 expression level elicits growth arrest in response
to as-APF. We observed an apparent inverse relationship between
p53 expression and expression of its negative regulator, MDM2, in
the TRT-HU1 immortalized bladder epithelial cell line, recently
developed by us [40], and in T24 bladder cancer cells (Fig. 2A).
These data suggest that p53 accumulation in response to as-APF
may involve MDM2, and that as-APF may block p53 ubiquitina-
tion and protein degradation as part of the mechanism by which it
increases p53 protein levels [39]. Time course western blot analysis
showed that as-APF treatment rapidly decreased MDM2 protein
at 2 h (,75% reduction) (Fig. 2B). In experiments where T24 cells
were treated with as-APF, we noted that MDM2 gene silencing
itself suppressed proliferation, and there was only a mild additive
effect of as-APF in the setting of MDM2 knockdown (Fig. 2C).
These data imply that as-APF inhibits T24 bladder cell
proliferation mainly through the MDM2 and p53 axis.
as-APF Suppresses p53 Ubiquitination and Cell
Proliferation
Consistent with the conclusion that p53 is regulated by MDM2,
which is downregulated in response to as-APF treatment, p53
protein levels fluctuated inversely and time dependently with
MDM2 in response to HB-EGF, a potent pro-proliferative growth
factor for bladder epithelial cells and an APF antagonist [27]
(Fig. 3A). Given this, we tested the association of p53/MDM2 in
response to HB-EGF [27]. Immunoprecipitation (IP) and western
blot analysis demonstrated that HB-EGF stimulated p53/MDM2
complex formation (Fig. 3B). Given the opposing responses of
MDM2 and p53 elicited by HB-EGF (Fig. 3A), the enhanced
association of p53 and MDM2 by HB-EGF stimulation (Fig. 3B)
supported the hypothesis that MDM2 may negatively regulate p53
expression, possibly by stimulating direct binding of MDM2 to
p53 following HB-EGF treatment [33–35]. Association of p53 and
MDM2 by HB-EGF was completely inhibited by as-APF (Fig. 3C),
and the level of p53 ubiquitination was suppressed by as-APF pre-
treatment (Fig. 3D). These findings suggest that as-APF inhibits
MDM2 binding to p53, and leads to p53 accumulation.
Furthermore, HB-EGF significantly abrogated the effect of as-
APF on cell growth, while as-APF blocked the enhancement of cell
proliferation by HB-EGF (Fig. 3E). Levels of HB-EGF were shown
to be lower in urine from IC/PBS patients in comparison to
normal controls, and HB-EGF levels were shown to increase,
while APF activity levels decreased, after cystoscopic hydrodisten-
tion, a common clinical procedure to relieve IC symptoms [41].
HB-EGF abrogated the effects of APF on human bladder
epithelial cells [25], and antagonized native APF-stimulated
p38MAPK signaling and cell cycle arrest [27,28]. Nutlin-3, a
small-molecule inhibitor of the p53-MDM2 interaction, upregu-
lated p53 levels in the T24 bladder cells (Fig. 3F) and resulted in
growth suppression (Fig. 3G). Taken together, these data suggest
Figure 2. as-APF downregulates MDM2, leading to inhibition of cell proliferation. (A) Inverse expression pattern of p53 and MDM2 in
bladder cell lines. Protein extracts were prepared from growing TRT-HU1, RT4 and T24 bladder cell lines for western blot analysis using antibodies
against MDM2, p53 and b-actin. (B) MDM2, an E3 ubiquitin ligase, is decreased in response to as-APF. T24 cells were treated with APF (1 mM) for the
indicated times (1, 2, 4, 6 or 8 h). Whole cell lysates were prepared for immnuoblot with anti-MDM2 antibody. Fold changes compared to time 0 were
calculated based on band intensities after normalization to b-actin. (C) Silencing of MDM2 decreases cell proliferation with or without as-APF
treatment. Transfected T24 cells with siCtrl or siMDM2 were incubated in 1 mM as-APF (or negative control peptide)-containing medium for 3 days.
Cell proliferation was determined by crystal violet assay. *p,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0050392.g002
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leading to p53 accumulation and cell growth inhibition.
as-APF Regulates Expression of the USP2a
Deubiquitinase and Stability of MDM2
The above findings raised the question of how MDM2 is
regulated in response to as-APF. A previous report by Stevenson
et al. demonstrated that MDM2 is a target of the ubiquitin specific
protease 2a (USP2a), a de-ubiquitinating enzyme [42]. Overex-
pression of USP2a promoted accumulation of MDM2 by reversing
ubiquitination and subsequent protein degradation, while reduced
USP2a destabilized MDM2 and caused accumulation of p53
protein [42]. We decided to assess whether USP2a affects p53
expression by modulating MDM2 stability in response to as-APF.
Time course western blot analysis demonstrated that as-APF
treatment rapidly decreased USP2a level within 30 min, while the
control peptide had no effect (Fig. 4A). Immunofluorescence
imaging of T24 cells treated with control (mock APF) or as-APF
peptides confirmed that USP2a (punctuate pattern, in red) rapidly
diminished and no USP2a was observed 2 h after treatment with
1 mM as-APF (Fig. 4B, i and ii). USP2a-GFP level (in green) was
reduced in response to APF treatment in T24 cells transiently
transfected with a USP2a-GFP expression construct (Fig. 4B, iii
and iv). In addition, in untreated T24 bladder cells, MDM2 and
USP2a (Fig. 4C), but not p53 and USP2a (data not shown),
formed a complex. These findings suggest the possibility that
USP2a plays a role in regulation of MDM2 and that USP2a may
stabilize MDM2 by competing with ubiquitin for binding to
MDM2, as suggested in the Stevenson et al. report [42]. Indeed,
when USP2a was silenced by siRNA, MDM2 protein levels and
proliferation were significantly reduced in as-APF-treated cells
(Fig. 4D and 4E), implying that USP2a is an important mediator
of MDM2 activity regulating bladder cell proliferation.
Figure 3. as-APF treatment antagonizes HB-EGF by regulation of MDM2 and p53. (A) MDM2 expression is negatively correlated with p53
level. T24 cells were serum starved for 16 h and stimulated with 10 ng/ml HB-EGF containing serum free medium. At 0, 2, 4, 6, and 8 h after treatment
cells were harvested and whole cell lysates were prepared for immunoblot analysis. Protein expression levels of MDM2 or p53 are shown normalized
to b-actin (right). (B) Association of p53 and MDM2. T24 cells were harvested after HB-EGF treatment for 0, 15 or 30 min for immunoprecipitation (IP)
with anti-p53 antibody. Western blot was then done with anti-MDM2 antibody to determine the binding of p53 and MDM2 in response to HB-EGF.
(C) as-APF reverses association of p53 and MDM2 induced by HB-EGF. T24 cells were incubated in as-APF (1 mM) and/or HB-EGF (10 ng/ml)
containing medium for 30 min. Whole cell lysates were subjected to co-IP and western blot analysis using antibodies against p53 and MDM2. (D) as-
APF alleviates the HB-EGF-induced p53 ubiquitination. Cells were stimulated with as-APF (1 mM) and/or HB-EGF (10 ng/ml) in the presence of MG132
(10 mM) for 30 min. Whole cell lysates were used for IP with anti-p53 antibody and following immunoblot analysis with anti-p53 antibody. (E)
Antagonistic effects of as-APF and HB-EGF on cell growth. T24 cells were incubated with as-APF (1 mM) and/or HB-EGF (10 ng/ml) containing medium
for 3 days and proliferation was determined by crystal violet assay. *p,0.05. (F) Inhibition of association between MDM2 and p53 by Nutlin-3
increases p53 expression. T24 cells were incubated in 10 mM Nutlin-3- or Vehicle-containing medium for 3 days. Immunofluorescence staining
showed that p53 level was increased by Nutlin-3. p53 appears red. Scale bar represents 10 mm. (G) Nutlin-3 decreases cell proliferation. T24 cells were
incubated in 10 mM Nutlin-3- or Vehicle-containing medium for the indicated times (0, 1, and 3 days). Cell proliferation was determined by crystal
violet assay. *p,0.05.
doi:10.1371/journal.pone.0050392.g003
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as-APF
We further expanded our findings suggesting a role for USP2a-
MDM2-p53 signaling in APF-mediated inhibition of cell growth.
Enforced expression of wild type USP2a (USP2a
WT) increased
MDM2 and decreased p53 levels (Fig. 5A and 5B). In comparison,
a catalytically inactive USP2a mutant, (USP2a
MUT) did not
promote enhanced MDM2 expression (Fig. 5C), suggesting that
USP2a enzyme activity is critically required for regulation of the
MDM2-p53 signaling pathway that responds to APF stimulation.
Bromodeoxyuridine (BrdU) staining, which allows detection of
proliferating cells in S phase, demonstrated that USP2a
WT
enhanced proliferation (Fig. 5C). We assessed the mechanism by
which USP2a alters cell proliferation using a cyclin D1 luciferase
promoter-reporter as a read-out because cyclin D1 has been
previously identified as a USP2a target as well as an important cell
cycle regulator in bladder cells [43]. USP2a activated the cyclin
D1 promoter in a concentration dependent manner (Fig. 5D).
USP2a also enhanced cyclin D1 protein expression and nuclear
localization (Fig. 5E and 5F), suggesting that USP2a plays a role in
proliferation by using cyclin D1 as a mediator. These data also
imply that complex formation between USP2a/MDM2 may be
required for MDM2 stabilization, leading to degradation of p53.
Based on these results, we thus hypothesized that reduced
USP2a elicited by as-APF may allow MDM2 degradation,
resulting in a subsequent increase in p53-mediated cell growth
inhibition. To test this hypothesis, we examined the effects of
enforced USP2a expression in the presence or absence of as-APF.
Immunofluorescence microscopy demonstrated that USP2a
WT
substantially sustained MDM2 levels in the presence of as-APF,
while control cells (Vector) showed almost no MDM2 expression
(Fig. 6B, upper panels). P53 expression was increased in response
to as- APF (Fig. 6B, left lower panels). However, when USP2a
WT
was overexpressed, p53 level was greatly reduced in response to
APF (Fig. 6B, right low panels), suggesting that enforced USP2a
expression impaired the effect of as-APF on MDM2 and p53. To
assess the effect of altered expression of USP2a, we analyzed cell
proliferation after transfection of T24 cells with USP2a
WT or
USP2a
MUT constructs. Compared to controls, USP2a
WT cells
were more proliferative in the absence or presence of as-APF,
while USP2a
MUT had no effect (Fig. 6C and 6D). No growth
suppression was observed in response to as-APF when USP2a
WT
was overexpressed, suggesting that active USP2a reverses the APF
inhibitory effect on proliferation; in comparison, USP2a
MUT did
not affect cell proliferation or the effects of APF (Fig. 6D).
as-APF Activates the USP2a-MDM2-p53 Network in
Human Non-malignant Bladder Epithelial Cells
To further examine the regulatory role of the USP2a-MDM2-
p53 network in APF-induced growth arrest, we performed
additional experiments using TRT-HU1 cells [40]. as-APF at
1 mM markedly increased levels of p53 and rapidly diminished
Figure 4. Regulation of USP2a and MDM2 in response to as-APF. (A) as-APF downregulates USP2a expression (immunoblot). T24 cells were
incubated with 1 mM as-APF or control peptides for the indicated times (0, 0.5, 1, 1.5, or 2 h). Western blot with anti-USP2a antibody showed that the
level of USP2a level was stably decreased in response to as-APF treatment, but this was only transiently reduced by control mock APF peptide. (B)
Reduced USP2a by as-APF treatment (IF staining). (i and ii) After incubation with 1 mM as-APF for 2 h, cells were fixed and stained with anti-USP2a
antibody and a Cy3-conjugated secondary antibody (red). Nuclei were counterstained with DAPI. Scale bar represents 10 mm. (iii and iv) USP2a
expression in T24 cells transfected with a GFP-USP2a construct was diminished in response to APF treatment. Green, USP2a. (C) Association of MDM2
and USP2a. Exponentially growing T24 cells were used for co-IP and western blot analysis with antibodies against USP2a and MDM2. (D) Knockdown
of USP2a results in reduced MDM2 expression. T24 cells were transiently transfected with USP2a siRNA (siUSP2a) or siCtrl, and whole cell lysates were
used for western blot analysis. (E) Gene silencing of USP2a inhibits cell proliferation. 3 days after transient transfection with siRNA of USP2a, cell
proliferation was measured by crystal violet.
doi:10.1371/journal.pone.0050392.g004
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A direct association between USP2a and MDM2 was shown by IP
and western blot in untreated cells (Fig. 7C). Knockdown of
USP2a by siRNA resulted in a decrease in MDM2 level as well as
inhibition of growth in the presence of as-APF (Fig. 7D). Enforced
expression of USP2a
WT, but not USP2a
MUT, abrogated the
growth inhibition seen following as-APF treatment (Fig. 7E).
Taken together, these results suggest that USP2a-MDM2-p53 is a
signaling axis that mediates the physiologic effects of APF in
bladder epithelial cells. A diagram of the USP2a-MDM2-p53
signaling network that is engaged in response to APF is shown in
Fig. 8.
Discussion
Despite growing clinical interest in IC/PBS, a symptom-based
bladder disease that causes chronic pain, increased frequency, and
urgency, the molecular basis of IC/PBS remains uncharacterized.
Because IC/PBS symptoms overlap with other common gyneco-
logic and urologic conditions (such as pelvic inflammatory disease,
urethritis, cystitis, and prostatitis), specific and unique diagnostic
markers are urgently needed.
We previously reported that the p53 signaling network is
activated by APF, a urine IC/PBS glycopeptide that produces
effects in primary normal bladder epithelial cells that resemble
changes seen in IC/PBS cell explants in vitro as well as changes
seen in the bladder of IC/PBS patient biopsies [20,39]. In this
Figure 5. Catalytically active USP2a, USP2a
WT, alters MDM2 and cyclin D1 expression. (A) Enforced expression of wild type USP2a
(USP2a
WT) enhances MDM2 level and decreases p53 expression (western blot). T24 cells were transfected with varying doses of USP2a
WT plasmid. 2
days later, whole cell lysates were prepared and subjected to western blot with MDM2 or p53 antibodies. Experiments were performed 3 times and
blot images are representative. Fold change was calculated based on band intensities and normalized to b-actin (right graph). (B) USP2a
WT, but not
catalytically inactive USP2a
MUT, enhances MDM2 expression (Western blot). T24 cells were transfected with Vector, USP2a
WT or USP2a
MUT constructs,
and prepared for western blot. Data are representative of at least 3 experiments. (C) Proliferation is enhanced by overexpression of USP2a
WT (BrdU
staining). 3 days after transfection with USP2a
WT construct (or Vector control), T24 cells were stained with BrdU staining reagent for visualization of
proliferating cells. Green indicates proliferating cells. Nuclei were stained with DAPI (Blue). (D) Cyclin D1 transcription is induced by USP2a
WT
(promoter assay). Cyclin D1 luciferase promoter construct, MDM2 and varying doses of USP2a
WT (0, 0.1, 1 or 2 mg) were transfected into T24 cells.
Three days after transfection, cyclin D1 promoter activity was measured by luciferase assay. *p,0.05. **p,0.005. (E–F) Cyclin D1 protein expression
and nuclear localization are increased by USP2a
WT overexpression (IF imaging). Immunofluorescence staining for cyclin D1 in T24 cells was performed
2 days after overexpression of USP2a
WT. Cells were fixed and stained with specific antibody to cyclin D1 (red) and mounted with DAPI (blue) solution.
Scale bar represents 10 mm. (F) Localization of cyclin D1 was quantified. N, only nuclear resident cyclin D1; C+N, localized in nucleus as well as
cytoplasmic compartments.
doi:10.1371/journal.pone.0050392.g005
USP2a-MDM2-p53 Pathway Sensitive to APF
PLOS ONE | www.plosone.org 6 December 2012 | Volume 7 | Issue 12 | e50392study, we sought to gain further insight into the mechanism by
which APF increased p53 levels in bladder epithelial cells. We
employed two new reagents in this study: (1) a synthetic form of
APF (as-APF), and (2) an immortalized, benign, and APF-
responsive bladder cell line that we recently developed [40]. Our
work defines a new mechanism of APF-mediated signaling, in
which a molecular network involving USP2a, MDM2, and p53, is
activated in bladder epithelial cells in response to as-APF. Our
findings support the following conclusions: (1) synthetic as-APF
decreases USP2a and MDM2 levels, (2) as-APF blocks a direct
association between p53 and MDM2, resulting in decreased p53
ubiquitination and protein degradation, and (3) the effect of as-
APF on bladder epithelial cell proliferation can be blocked by
enforced expression of USP2a.
USP2a was previously shown to be a regulator of the MDM2/
p53 pathway in a range of tumor cells, including oral squamous
cell carcinoma, testicular embryonal carcinoma, prostate carcino-
ma, and breast carcinoma [44–46]. USP2a, which forms a
complex with MDM2 [42], the MDM2 homologue MDMX
[47,48], FASN (fatty acid synthase) [49], cyclin D1 [50] and
Aurora A [51], is positively linked to tumor progression [52].
Downregulation of USP2a accelerates ubiquitin-dependent deg-
radation of proteins such as MDM2, FASN and EGFR
[42,47,49,50]. However, a role for USP2a has not been established
in any bladder diseases, including bladder cancer and IC/PBS.
Our findings suggest that the altered ubiquitination status
triggered by APF, a bioactive peptide, results in the impaired
regulation of key proteins during pathological conditions in the
bladder.
Previous studies using native APF, which was HPLC-purified
from human bladder epithelial cells [39], demonstrated that p53
plays a critical role in APF-induced inhibition of cell proliferation.
Synthetic as-APF was also recently shown to increase p53 mRNA
and protein expression in T24 bladder carcinoma cells [26]. Our
results here suggest that USP2a and MDM2 are additional
components of the p53 network as upstream regulators of p53 in
response to as-APF-stimulated signal activation in bladder cells.
In addition to altered p53 signaling, several interesting other
signaling abnormalities have been observed in cell explants from
patients with IC/PBS and APF-stimulated bladder cells [28].
For example, in APF-responsive T24 cells, MAPK signaling was
also shown to be involved in APF-mediated cell growth arrest
[27]. APF rapidly and transiently activates p38MAPK, which
antagonizes Erk/MAPK signaling [27]. APF has also been
shown to inhibit Akt phosphorylation and increase downstream-
specific phosphorylation of b-catenin [26]. APF-responsive cells
further exhibit altered expression of genes known to play a role
in tight junctions, cellular proliferation and tumorigenesis (e.g.
E-cadherin, vimentin, and zonula occludens protein-1) [21].
Very recently, a quantitative proteomics study performed by our
group identified a global network of APF-regulated proteins,
within which b-catenin is a key node [53]. Expression levels of
b-catenin and a downstream target, cyclooxygenase-2, were
altered in epithelial cells explanted from IC bladder biopsies
compared with control tissues [53]. However, the relationship of
Figure 6. USP2a
WT blocks the growth inhibitory effect of as-APF. (A–B) USP2a
WT abrogated as-APF’s effect on MDM2 and p53 levels (IF
imaging). MDM2 or p53 were labeled with specific primary antibodies and Cy3.5 conjugated secondary antibody (red). Nuclei were stained with DAPI
(Blue). (C–D) Enforced expression of USP2a
WT alleviates the as-APF-induced growth inhibition. T24 cells were transiently transfected with vector,
USP2a
WT or USP2a
MUT constructs. One day after transfection, cells were incubated in the 1 mM as-APF containing serum free medium for an additional
3 days. Proliferation was measured by crystal violet assay and representative cell images are shown in C.
doi:10.1371/journal.pone.0050392.g006
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remains to be determined, and the relationship of any of these
pathways to the characterized APF receptor CKAP4 is also not
fully understood.
Our results have provided evidence that APF perturbs protein
stability through a balance of ubiquitination and deubiquitination
arising from the action of the UPS2a/MDM2/p53 network. Our
biochemical and functional analyses suggest that the USP2a-
MDM2-p53 axis may be pertinent to pathologic changes in the
bladder wall associated with IC/PBS. To our knowledge, this is
the first evidence implicating USP2a and MDM2 in biological
effects induced by APF. These findings therefore expand our
understanding of the mechanism whereby APF inhibits bladder
epithelial cell proliferation, and suggest that components of this
mechanism might serve as useful clinical features, diagnostic
indicators or as novel therapeutic targets. In particular, a strategy
targeting USP2a degradation or complex formation between
USP2a/MDM2/p53 may be fruitful in the development of
therapeutic approaches to IC/PBS.
Experimental Procedures
Reagents
as-APF and nonglycosylated nagative control peptides were
purchased from PolyPeptide Laboratories, Inc. (San Diego, CA),
and they were synthesized according to previously described
methods [15,26,38]. Heat inactivated and dialyzed fetal bovine
serum (FBS) and Lipofectamine 2000 were purchased from
Invitrogen (Carlsbad, CA). Micro BCA protein assay kit and
protease inhibitor cocktail tablets were obtained from Pierce
(Rockford, IL) and Roche Diagnostics (Basel, Switzerland).
Premade SDS-PAGE (4–20%) gels, Coomassie Blue R-250
staining solution and destaining solution were from Bio-Rad
(Hercules, CA). Small interfering RNAs (siRNAs) and OFF-
Figure 7. as-APF increases p53 expression by modulating USP2a and MDM2 in TRT-HU1, immortalized human normal bladder
epithelial cells. (A) p53 levels were enhanced by as-APF treatment. TRT-HU1 cells were incubated in as-APF-containing serum free medium for 3
days before harvesting cells for western blot analysis with anti-p53 antibody. (B) Endogenous USP2a level is rapidly decreased in response to as-APF
treatment in TRT-HU1 cells. (C) Association of USP2a and MDM2 in TRT-HU1 cells. IP was performed using whole cell lysates from TRT-HU1 cells in
exponential growth with anti-USP2a antibody, followed by western blot analysis with antibodies against USP2a and MDM2. Normal mouse IgG was
used as an IP control (Ctrl). (D) USP2a loss decreases MDM2 and cell proliferation. TRT-HU1 cells were transiently transfected with siRNA of USP2a (or
siCtrl). One day after transfection, cells were treated with 1 mM as-APF (or mock peptide)-containing medium. Three days later, cells were harvested
for western blot analysis and proliferation assay. *p,0.05, NT, non-transfected cells. (E) Proliferation is enhanced by overexpression of USP2a
WT, but
not by USP2a
MUT. Cells transfected with USP2a
WT, USP2a
MUT or vector control (Vec) constructs were treated with 1 mM as-APF or mock peptide for 3
days. Western blot and proliferation assay were performed as above. Data are represented as mean +/2 SD. *p,0.05.
doi:10.1371/journal.pone.0050392.g007
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diamidino-2-phenylindole (DAPI) was purchased from Vector
Laboratories (Burlingame, CA). Antibodies against MDM2, p53,
USP2a, cyclin D1 and b-actin, were purchased from Abcam
(Cambridge, MA), CalBiochem (San Diego, CA), ABGENT (San
Diego, CA) and Cell Signaling Technology (Danvers, MA),
respectively. All other reagents were obtained from Sigma-Aldrich
or Promega (Madison, WI).
Cell Culture
APF-responsive human bladder cancer T24 cells, or RT4 cells
were obtained from the American Type Culture Collection
(ATCC). Cells were cultured in McCoy’s 5A medium containing
Figure 8. Diagram proposing the points at which the USP2a-MDM2-p53 network mediates the effect of APF on urothelial cell
proliferation.
doi:10.1371/journal.pone.0050392.g008
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100 mg/mL streptomycin at 37uC in a humidified incubator with
5% CO2. Immortalized human normal bladder epithelial TRT-
HU1 cells were developed and maintained as described [40]. For
transient transfection, cells were grown to ,80% confluence in
100 mm dishes, at which time they were transiently transfected
with plasmid constructs containing cDNAs of MDM2, USP2a
WT
or catalytically inactive USP2a (USP2a
MUT), which were cloned
into pEGFP and used for transfection. To silence protein
expression, cells were transfected with 80 nmol/L of small
interfering RNAs (siRNAs) against p53, MDM2 or USP2a
(Dharmacon, Lafayette, CO) using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA) according to the manufacturer’s instructions.
OFF-TARGET siRNAs were used as controls.
Cell Proliferation Assay
T24 or TRT-HU1 cells were plated onto 6-well culture plates at
a density of 1610
3 cells per well in standard growth medium.
When cells grew to ,80% confluence, they were serum-starved for
16 h followed by incubation in serum-free medium containing
1 mM as-APF or inactive nonglycosylated control peptide for an
additional 3 days. Cell proliferation was quantified by crystal violet
staining. Briefly, cells were stained with crystal violet solution and
quantified by dissolving stained cells in 10% acetic acid solution.
Colorimetric reading was done by absorbance measurement at
570 nm.
Western Blot Analysis
Whole cell lysates were prepared as described [53]. Proteins
were separated by SDS-PAGE and transferred onto nitrocellulose
membranes for immunoblotting analysis. ImageJ (v1.410, rsbweb.-
nih.gov/ij) was used for densitometry, which was followed by
normalization against corresponding loading control bands.
Immunofluorescence Microscopy
Cells were fixed with 4% paraformaldehyde and incubated with
1:500 primary antibodies against p53, MDM2, USP2a or cyclin
D1 (diluted 1:500 in PBST) prior to incubation with 1:250 Cy3.5-
conjugated secondary antibody (red). Slides were mounted in
Vectashield with DAPI and observed under a Zeiss microscope
(Burlingame, CA). For BrdU staining, cells were incubated in
labeling medium for 1 h before fixation and staining with anti-
BrdU antibody according to the manufacturer’s instructions
(Roche, Penzberg, Germany).
Promoter Luciferase Assay
T24 cells were transiently transfected with a cyclin D1
promoter-luciferase construct, which was kindly provided by Dr.
Osamu Tetsu at University of California, San Francisco [54] and
varying concentration of USP2a
WT. Two days after transfection
luciferase activity was measured in whole cell lysates. As described
in the manufacturer’s protocol, firefly and Renilla luciferase
activities were measured with the Promega Dual-Luciferase
reporter system (Promega, Madison, WI). Total protein was used
for normalization. All experiments were carried out in triplicate
and repeated 3 times using different preparations of plasmids.
Statistical Analysis
The mean of 3 or more replicates was used as average. Data is
presented as mean 6 SD. The p-values were calculated using a
standard unpaired Student’s t-test for simple comparisons.
Statistical significance is displayed as p,0.05 (one asterisk) or
p,0.005 (two asterisks).
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